• Healthcare Providers Direct (Lawrenceville, New Jersey) reported the release of ImmunoDip, a rapid screening test to detect microalbuminuria, an early indicator of chronic kidney disease in diabetic patients. Microalbuminuria occurs when a malfunctioning kidney leaks small amounts of albumin into the urine. Sometimes early kidney damage can be reversed, making early diagnosis critical. ImmunoDip can detect as little as 18 mg/l of albumin in the urine. Microalbuminuria is indicated at 20-30 mg/l. With ImmunoDip, physicians can complete the test in their office with a negative or positive indication within three minutes. Healthcare Providers Direct makes rapid diagnostic tests.
  • IDEV Technologies (Houston) received FDA clearance for a new Supera biliary stent delivery catheter. The improved Supera is indicated for the palliative treatment of biliary strictures produced by malignant neoplasms. The Supera offers a retrieval capability of up to 95% for a partially deployed Supera biliary stent. The Supera offers more than 360% greater radial force than other commercially available laser cut nitinol tube self-expanding biliary stents. IDEV makes minimally invasive stent technologies.
  • Ikonisys (Dallas) said that it has begun a clinical trial evaluating its breakthrough test for early detection of chromosomal abnormality trisomy 21. The trial is intended to establish accuracy and efficacy in the detection of trisomy 21 in circulating fetal cells. Ikonisys expects this solution to be the first in a suite of non-invasive cell-based fetal tests. Ikonisys makes non-invasive, cell-based diagnostic solutions.